1
Clinical Trials associated with Autologous melanoma lysate-pulsed autologous dendritic cell vaccine (MSCNRIO) / Unknown statusPhase 1/2IIT Adjuvant Vaccination With Melanoma Antigen Pulsed Dendritic Cells (DCs) in Stage III Melanoma Patients
RATIONALE: Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best way to give melanoma vaccine in treating patients with stage III melanoma after surgery to remove the lymph nodes.
100 Clinical Results associated with Autologous melanoma lysate-pulsed autologous dendritic cell vaccine (MSCNRIO)
100 Translational Medicine associated with Autologous melanoma lysate-pulsed autologous dendritic cell vaccine (MSCNRIO)
100 Patents (Medical) associated with Autologous melanoma lysate-pulsed autologous dendritic cell vaccine (MSCNRIO)
100 Deals associated with Autologous melanoma lysate-pulsed autologous dendritic cell vaccine (MSCNRIO)